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Kaposi’s sarcoma herpesvirus (KSHV), also known as human
herpesvirus 8, is now established as the aetiologic agent of
Kaposi’s sarcoma (KS) (Antman and Chang, 2000). Most KSHV-
infected people are asymptomatic. However, with immunosup-
pression induced by human immunodeficiency virus type 1 (HIV),
risk for KS increases substantially (Martin et al, 1998). 
Several lines of evidence suggest that KSHV is also a cause of
lymphoma in HIV-infected persons. KSHV is found within circu-
lating B lymphocytes (Blackbourn et al, 1997) and is closely
related to Epstein–Barr virus and herpesvirus saimiri, which each
cause lymphoma (International Agency for Research on Cancer,
1997, p. 375–494). KSHV might stimulate lymphocytes to prolif-
erate abnormally through virally encoded homologues of cytokines,
such as v-interleukin 6, or proteins that interfere with cell cycle
control, such as v-cyclin or latent nuclear antigen (Moore et al,
1996; Radkov et al, 2000). KSHV is consistently detected in
acquired immunodeficiency syndrome (AIDS)-associated primary
effusion lymphoma, a rare tumour arising from pleura, pericardium
or peritoneum (Cesarman et al, 1995; Nador et al, 1996; Gessain
et al, 1997). The virus is also found in lymphomas occurring in
multicentric Castleman’s disease (Dupin et al, 2000). Nonetheless, it
remains uncertain whether KSHV actually causes these lymphomas
or other lymphoma variants among persons with AIDS. 
There are few systematic data on the relationship between
KSHV and various malignancies, including lymphoma. In the
present study, we compared the incidence of various malignancies
in persons with AIDS-associated KS (all of whom were KSHV-
infected) with the incidence in other persons with AIDS (most of
whom were KSHV-uninfected). With this design, a significant
association with KS served to identify tumours for which KSHV
might be aetiologic. An advantage of our registry-based study was
its large size, including over 189 000 persons with AIDS. 
MATERIALS AND METHODS 
Study subjects and matching 
We used data from the AIDS-Cancer Match Registry study. As
described elsewhere (Frisch et al, 2001), this study provides data
on cancer incidence in persons with AIDS, through linkage of
cancer and AIDS registries from eleven areas of the United States,
namely, the states of Connecticut, Florida, Illinois, Massachusetts,
New Jersey, and New York, and the metropolitan areas of Atlanta,
Los Angeles, San Diego, San Francisco, and Seattle. Thus,
included subjects were those persons with an AIDS diagnosis (as
documented in an AIDS registry) occurring in the period of regis-
tration covered by the relevant cancer registry, and the occurrence
of malignancies in these subjects was identified using the cancer
registries. The period of registration varied by cancer registry, but
all included 1983–1994, except San Diego, where registration
began in 1988, and no data were available after 1996. In the
present study, 2 areas were excluded, because the cancer registry
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included a substantial number of inaccurately diagnosed cases of
KS or provided data only on first malignancies. 
All subjects were classified according to whether they devel-
oped KS at any point during observation, based on diagnoses
recorded in either AIDS or cancer registries. For this purpose, we
considered cases of KS dated from AIDS onset (under the defini-
tion of AIDS, no cases of KS occurred before AIDS) until 60
months after AIDS onset. 
Incidence of malignancies 
Using diagnoses recorded in the cancer registries, we calculated
the incidence of various malignancies from 4 to 27 months after
AIDS onset (post-AIDS period). This 2-year period excluded the 3
months immediately following AIDS (AIDS period), since cancer
ascertainment would have been elevated at that time due to height-
ened diagnostic efforts at AIDS onset. Although we also had data
on malignancies arising 28–60 months after AIDS onset, AIDS-
related mortality increases steeply during this late period, and we
did not have complete survival data. Therefore, to avoid inadver-
tently including person-time for subjects with unreported deaths
(and thus underestimating incidence), we censored follow-up at 27
months after AIDS onset. 
Observed malignancies were categorized by site (and, for
lymphomas, leukaemias, and melanoma skin cancer, by histology)
based on the second edition of International Classification of
Diseases for Oncology (ICDO-2) (Percy et al, 1990). Under the
Working Formulation (Non-Hodgkin’s lymphoma pathologic clas-
sification project, 1982), non-Hodgkin lymphomas were classified
as low-grade (ICDO-2 codes 9670–9671, 9691–9696); inter-
mediate-grade (9672–9676, 9680–9683, 9697–9698); high-grade,
further classified as Burkitt (9687), large cell immunoblastic
(9684), or other high-grade (9685–9686); or other/unspecified (all
other codes from 9590–9595 and 9670–9714). For calculating
post-AIDS incidence of non-Hodgkin lymphomas, we excluded
subjects who had non-Hodgkin lymphoma in the AIDS period.
Similarly, for cervical cancer, we excluded women diagnosed with
cervical cancer in the AIDS period. 
Statistical analysis 
For each malignancy, association with KS was assessed by calcu-
lating the relative risk, defined as the post-AIDS incidence in
subjects with KS divided by the post-AIDS incidence in subjects
without KS. We calculated 2-sided 95% confidence intervals for
these relative risks using an exact method (Breslow and Day,
1987, pp. 91–95). 
For malignancies significantly associated with KS, we used
Poisson regression (McCullagh and Nelder, 1989) to adjust the
relative risks for gender, age at AIDS (less than 30, 30–39, 40–49,
50+ years), race (white, black, Hispanic, other/unknown), and
calendar year (1978–1984, 1985–1988, 1989–1992, 1993–1996).
We also controlled for HIV risk group (homosexual male vs.
other), because most cases of AIDS-associated KS arise in homo-
sexual males, and this group, compared with other risk groups,
may have higher risk for some cancers (e.g. anal cancer) due to
factors other than KSHV infection. In an additional analysis, we
also adjusted relative risks for CD4 counts at AIDS, which were
available for a minority of subjects. 
Levels of continuous variables were compared between groups
using the 2-sample t-test, and the distributions of categorical
variables were compared using the χ 2 statistic. Matlab (Version 5,
Math Works, Natick, MA) and S-Plus (Version 2000, MathSoft,
Seattle, WA) were utilized for calculations. A 5% level of statis-
tical significance was used. 
We calculated the attributable risk percent (the proportion of
cancer cases, among those with KS, attributable to having KS) as
(RR–1)/RR, and the population-attributable risk percent (the
proportion of cancer cases, in the entire AIDS population, attribut-
able to having KS) as pKS × (RR–1)/[pKS × (RR–1) +1], where RR
was the adjusted relative risk for cancer, given KS, and pKS was the
prevalence of KS in the population (Hennekens and Buring, 1987,
pp. 87–93). Because KS served to identify persons with KSHV
infection, these figures are an estimate of the proportion of cases
attributable to KSHV infection. 
RESULTS 
Study subjects 
We studied 189 159 subjects: 26 972 (14%) with KS (occurring at
any time during follow-up) and 162 187 (86%) without KS
(Table 1). The majority (92%) of subjects with KS were homo-
sexual males, and most were white. In contrast, among subjects
without KS, only 47% were homosexual males and 57% were
black or Hispanic (Table 1). CD4 counts at AIDS diagnosis were
available for 67 896 subjects (36%). Among subjects with known
CD4 counts, subjects with KS were slightly more immunocompro-
mised than those without KS (mean CD4 counts at AIDS 91 vs.
115 cells mm–3, P = 0.0001). 68% of subjects with KS had CD4
counts below 100 cells mm–3 at AIDS, compared with 55% of
subjects without KS. Age did not differ between the 2 groups. 
Relative risks for malignancies 
For the post-AIDS period, Table 2 presents relative risks associ-
ated with KS, for each of the examined malignancies. Unadjusted
relative risks were significantly elevated for several histologic
categories of non-Hodgkin lymphoma: intermediate grade
lymphomas (relative risk 1.50, 95% confidence interval (CI)
1.26–1.78), high-grade large cell immunoblastic lymphoma
(2.44, 95% CI 2.00–2.96), and other/unspecified lymphoma (1.45,
95% CI 1.27–1.66). The increase in large cell immunoblastic
lymphoma (IBL) resulted in an elevated relative risk for all types
of high-grade lymphoma combined (2.06, 95% CI 1.74–2.45). In
analyses adjusted for gender, risk group, age, race, and calendar
year, IBL remained associated with KS (adjusted relative risk
1.58, 95% CI 1.29–1.93), but intermediate-grade lymphoma and
other/unspecified lymphoma were no longer significantly associ-
ated with KS (relative risks 1.05, 95%CI 0.88–1.26, and 1.02,
95%CI 0.89–1.18, respectively). Relative risks for Hodgkin
disease, leukaemias, and multiple myeloma were not elevated
(Table 2). 
For other malignancies (Table 2), only miscellaneous
(‘other/unknown’) tumours were significantly associated with KS
(unadjusted relative risk 1.88, 95%CI 1.35–2.59; adjusted relative
risk 1.69, 95%CI 1.19–2.39). Among subjects with KS, 34 of these
miscellaneous tumours (65%) were classified as ‘malignant
neoplasm’ with unknown primary site, compared with 57 (36%)
among other subjects (P = 0.0004). Among miscellaneous
tumours, tumours were noted at 10 separately specified sites, but
none occurred in excess among those with KS (data not shown). 1300 EA Engels et al 
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Large cell immunoblastic lymphoma (IBL) 
There were 506 IBLs, with 151 occurring in individuals with KS
(incidence 0.42%/year) and 355 occurring in individuals without
KS (0.17%/year). As noted, the association between KS and IBL
was significant even after adjustment for gender, risk group, age,
race, and calendar year (adjusted relative risk 1.58, 95%CI
1.29–1.93). In an analysis restricted to subjects with CD4 counts at
AIDS, further adjustment for CD4 count did not affect the relative
risk (1.50, 1.07–2.10). 
The strength of association between KS and IBL did not differ
significantly across strata defined by gender and risk group, race,
or CD4 count at AIDS (Table 3), or during different calendar
periods (data not shown). However, there was some evidence that
the strength of association varied across age groups (P = 0.06,
Table 3). Among subjects less than 30 years old at AIDS, the rela-
tive risk of IBL associated with KS was 1.19 (95%CI 0.63–2.26),
which was significantly less than the relative risk among older
subjects (2.68, 95%CI 2.19–3.28; P = 0.01 for difference in rela-
tive risks). Even after adjustment for gender, risk group, race, and
calendar year, relative risk of IBL associated with KS was lower
for subjects younger than 30 years (P = 0.01). 
Primary sites of IBLs among subjects with KS were: lymph
node (81 cases, 54%), brain (33 cases, 22%), and other sites (37
cases, 25%). Sites of IBLs among the other subjects were similar:
lymph node (192 cases, 54%), brain (64 cases, 18%), and other
sites (99 cases, 28%). Notably, among persons with KS, only one
IBL (0.7%) was identifiable as a primary effusion lymphoma, with
pleura as the primary site. 3 subjects without KS had IBLs arising
in the heart. There were no IBLs with peritoneum as primary site. 
Immunophenotype was available for 178 IBLs (35%).
Immunophenotyping became more common over time, with data
available for 0 of 8 IBLs occurring in 1978–1984, 23 of 99 (23%)
occurring in 1985–1988, and 155 of 399 (39%) occurring in
1989–1996. For IBLs with immunophenotyping, 168 (94%) were
B cell, 9 (5%) were T cell, and one (1%) had neither B nor T cell
markers. The occurrence of B cell IBL was significantly associ-
ated with a diagnosis of KS (unadjusted relative risk 2.64, 95%CI
1.87–3.69; adjusted relative risk 1.90, 1.35–2.68). T-cell IBL was
also associated with KS, although not significantly (unadjusted
relative risk 2.87, 0.46–13.44; adjusted relative risk 2.25,
0.52–9.76). 
Using the adjusted KS-associated relative risk of 1.58 for IBL,
we calculated the proportion of IBL cases attributable to KSHV,
assuming that infection with this virus explained the association
with KS and that the association was causal. Among persons with
KS, 37% of IBLs were attributable to KSHV (attributable risk
percent, 37%). Among all persons with AIDS, 8% of IBLs were
attributable to KSHV (population attributable risk percent, 8%). 
DISCUSSION 
The most important finding in this study was the demonstration of
a relationship between large cell immunoblastic lymphoma (IBL)
and KS. Unique among the 37 specified types of malignancy that
we examined, IBL was the only tumour significantly associated
with KS both in unadjusted analyses and in analyses adjusted for
possible confounding factors, including HIV risk group and CD4
count. The association between KS and IBL was not likely due to
primary effusion lymphoma occurring among our subjects.
Primary effusion lymphomas have an immunoblastic histology
(Nador et al, 1996), but among our study subjects with KS, only
one IBL arose in a serous body cavity (pleura). 
Our findings prompt consideration of the possibility that KSHV
is aetiologically involved in some AIDS-associated IBLs. As a
consequence of our study design, the excess of IBLs that we
observed occurred in persons who also had KS. Thus, our results
may indicate that specific defects in immune control of KSHV
predispose some immunosuppressed individuals to develop either
or both of these tumours. On the basis of the magnitude of associ-
ation between KS and IBL, we estimated that KSHV may be
present and etiologically important in 37% of IBLs arising in
persons with KS (attributable risk percent 37%). Notably, the esti-
mates of relative risk and attributable risk may have been too low,
because some subjects in the referent group (those without KS)
Table 1 Characteristics of study subjects 
Characteristic Subjects with Kaposi’s sarcoma  Subjects without Kaposi’s sarcoma  P value 
(n = 26 972) (n = 162 187)
Gender and risk group, n (%) < 0.0001 
Homosexual males 24 684 (92) 77 034 (48) 
Non-homosexual males 1842 (7) 55 769 (34) 
Females 446 (2) 29 384 (18) 
Age at AIDS, mean (sd) 37 (8) 37 (10) 0.54 
Race, n (%) < 0.0001 
White 18 796 (70) 66 916 (41) 
Black 3581 (13) 57 387 (35) 
Hispanic 4179 (15) 35 831 (22) 
Other/unknown 416 (2) 2053 (1) 
CD4 count at AIDS (cells/mm3), n (%)a 0.0001 
0–24 2605 (35) 16 600 (28) 
25–49 1142 (15) 7116 (12) 
50–99 1409 (19) 9757 (16) 
100–149 880 (12) 8449 (14) 
150+ 1495 (20) 18 443 (31) 
Mean CD4 count (SD) 91 (125) 115 (144) 
aFor CD4 count at AIDS, 19 441 subjects (72%) with Kaposi’s sarcoma and 101 822 subjects (63%) without Kaposi’s sarcoma had missing values. Cancers associated with KS in AIDS 1301
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were also KSHV-infected. Nonetheless, it seems likely that the
pathogenesis of IBL is complex and multifactorial. Epstein–Barr
virus is found in the majority of IBLs and primary effusion
lymphomas (Shibata et al, 1993; Nador et al, 1996), and it is
possible that this virus acts in concert with KSHV to cause IBL. 
Laboratory data, though scant, lend support to our epidemiolog-
ical findings. In their original description of KSHV in primary
effusion lymphoma, Cesarman et al did not find KSHV in any
of 8 other AIDS-associated lymphomas characterized as
‘immunoblastic plasmacytoid’ in histology (Cesarman et al,
1995). Other investigators subsequently found KSHV in 17–22%
of IBLs arising outside the pleura (Otsuki et al, 1996; Gessain
et al, 1997; Boye Hansen et al, 2000). The level of KSHV in posi-
tive cases was low, raising the possibility that the virus was present
only in normal circulating B lymphocytes within these tumours.
However, in a recent preliminary report, Cesarman and Knowles
described the presence of KSHV in high copy number in tumour
cells from 4 additional AIDS lymphomas, all of which were non-
effusion IBLs (Cesarman and Knowles, 1999). Although these
studies were small, overall they are consistent with KSHV being
present and playing a role in a minority of IBL cases arising in
AIDS, and are in accord with our estimate of population attribut-
able risk (8%). Other histologic types of lymphoma (e.g. Burkitt or
Burkitt-like tumours) have consistently been KSHV-negative in
laboratory studies (Cesarman et al, 1995; Otsuki et al, 1996;
Gessain et al, 1997). 
Additional, conflicting data on the relationship between KSHV
and AIDS-associated non-Hodgkin lymphoma are provided by 2
other studies. Using clinical records and autopsy material, Ridolfo
and colleagues identified 60 cases of non-Hodgkin lymphoma in
363 persons dying with AIDS (Ridolfo et al, 1996). 16 of these
lymphomas were found in persons with KS, of which 13 (81%)
were  ‘large-cell immunoblastic plasmacytoid’ in histology.
Notably, individuals whose AIDS index diagnosis was KS were
significantly more likely to develop non-Hodgkin lymphoma than
those with the more common index diagnosis of Pneumocystis
carinii pneumonia (relative risk 5.3). On the other hand, Gérard
et al observed no difference in KSHV seroprevalence between 63
AIDS lymphoma cases and 126 HIV-infected controls (Gerard
et al, 2001). A limitation of the Gérard study, however, was that
cases and controls were matched for history of KS, which might
have eliminated some differences in KSHV prevalence. Also,
serological assays for KSHV can misclassify infection status
(Engels et al, 2000). 
Lymphomas arising in multicentric Castleman’s disease could
partially explain the relationship between KS and IBL. Among
HIV-infected persons, KS is associated with the plasmablastic
variant of multicentric Castleman’s disease (Soulier et al, 1995;
Dupin et al, 2000). In multicentric Castleman’s disease, KSHV is
found in plasmablasts in the mantle zone of involved lymph nodes
and in secondary plasmablastic lymphomas (Dupin et al, 2000).
Plasmablastic lymphomas closely resemble IBL histologically
(Dupin et al, 2000; Anagnostopoulos et al, 2001). Indeed, the
ICDO-2 lacks a code for plasmablastic lymphoma, and plas-
mablastic lymphoma cases might have been classified as IBLs in
our study. Nonetheless, multicentric Castleman’s disease is rare
(Oksenhendler et al, 1996) and is unlikely to account entirely for
our findings. 
In our study, the finding of an association between IBL and KS
was given strength by its consistency across strata defined by HIV
risk group, gender, race and CD4 count. This consistency argues
Table 2 Relative risks for malignancies in association with Kaposi’s
sarcoma 
Site, histology nKS nno KS Relative risk (exact 95% CI)a
Non-Hodgkin lymphoma 632 2,260 1.60 (1.47–1.75) 
Low-grade 5 22 1.30 (0.39–3.53) 
Intermediate-grade 169 648 1.50 (1.26–1.78) 
High-grade 186 517 2.06 (1.74–2.45) 
Burkitt 16 70 1.31 (0.71–2.28) 
Immunoblastic 151 355 2.44 (2.00–2.96) 
Other high-grade 19 92 1.19 (0.68–1.96) 
Other/unspecified 272 1,073 1.45 (1.27–1.66) 
Leukaemia 3 24 0.72 (0.14–2.37) 
Acute myeloid 0 10 0 (0–2.01) 
Acute lymphoblastic 1 1 5.76 (0.07–452) 
Chronic myeloid 0 1 0 (0–109) 
Chronic lymphocytic 0 1 0 (0–109) 
Other/unspecified 2 11 1.05 (0.11–4.80) 
Hodgkin disease 8 59 0.78 (0.32–1.64) 
Multiple myeloma 3 10 1.73 (0.31–6.71) 
Oral cavity and pharynx 7 42 0.96 (0.36–2.16) 
Oesophagus 2 8 1.44 (0.15–7.21) 
Stomach 3 16 1.08 (0.20–3.77) 
Small intestine 0 2 0 (0–20.0) 
Colon 5 15 1.92 (0.55–5.55) 
Rectum 2 19 0.61 (0.07–2.51) 
Anus 5 33 0.87 (0.27–2.25) 
Liver 2 19 0.61 (0.07–2.51) 
Pancreas 0 11 0 (0–1.80) 
Upper respiratory sites 2 19 0.61 (0.07–2.51) 
Lung 22 162 0.78 (0.48–1.22) 
Kidney 0 15 0 (0–1.27) 
Bladder 1 7 0.82 (0.02–6.40) 
Breast 0 9 0 (0–27.2) 
Ovary 0 1 0 (0–1310) 
Uterus 0 4 0 (0–76.9) 
Cervix 2 37 3.71 (0.43–14.4) 
Vulva and vagina 0 8 0 (0–31.3) 
Testis 6 16 1.79 (0.57–4.82) 
Prostate 6 22 1.30 (0.43–3.32) 
Penis 0 5 0 (0–3.92) 
Thyroid 3 3 5.76 (0.77–43.0) 
Central nervous system 7 40 1.01 (0.38–2.27) 
Melanoma 3 19 0.91 (0.17–3.09) 
Musculoskeletal sites 5 9 3.20 (0.84–10.6) 
Other/unknown 52 159 1.88 (1.35–2.59) 
Abbreviations: nKS and nno KS, number of malignancies occurring in subjects
with or without Kaposi’s sarcoma, respectively; CI, confidence interval. 
aRelative risks that are in italic are statistically significant (P < 0.05). All
confidence intervals are two-sided 95% intervals, except when the observed
relative risk is zero, in which case the one-sided 95% confidence interval is
shown. 1302 EA Engels et al 
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against the possibility that unknown factors other than KSHV
infection explain the observed association between KS and IBL.
Interestingly, this association was strongest in persons at least 30
years old at AIDS onset. KSHV-related risk for IBL may be higher
in older individuals due to loss of control of KSHV infection with
aging, accumulation of somatic genetic errors, or acquisition of
additional cofactors for lymphomagenesis. Alternatively, the asso-
ciation between KS and IBL could have been diluted in younger
subjects if clinically inapparent KSHV infection was especially
common in that subgroup. Arguing against this second explanation,
limited data from cohort studies of homosexual men do not suggest
markedly higher KSHV prevalence among younger men (e.g., those
born after 1955) (Martin et al, 1998; Melbye et al, 1998).
As noted, the association between KS and IBL was specific.
After we adjusted for possible confounders, no other type of
lymphoma was related to KS. Risk was increased for miscella-
neous tumours, but many of these had non-specific histological
codes and may have been misclassified cases of KS. Risk for
myleoma was not elevated, which argues against a role for KSHV
in this disease despite the controversial identification of KSHV in
cultured bone marrow stromal cells from myeloma patients
(Berenson and Vescio, 1999; Tarte et al, 1999). Similarly, prostate
cancer risk was not increased, even though some epidemiological
evidence implicates a sexually transmitted agent (Hayes et al,
2000), and KSHV has been variably found in prostate tissue
(Monini et al, 1996; Staskus et al, 1997) and semen (Monini et al,
1996; Howard et al, 1997; Pauk et al, 2000). 
Our study complements several previous systematic studies of
cancer in KSHV infection. In a survey of South African cancer
patients, Sitas et al did not find elevated KSHV-seroprevalence
associated with cancers other than KS (Sitas et al, 1999). A poten-
tial limitation of that study, however, was its reliance on antibody
testing to diagnose KSHV infection (Engels et al, 2000). Using a
design similar to that of our study, Biggar et al did not find an
excess incidence of malignancies among HIV-uninfected persons
with KS (Biggar et al, 1994). On the other hand, among HIV-
uninfected Israelis with KS, Iscovich and colleagues noted a 4-fold
excess of non-Hodgkin lymphoma and no other elevations in
cancer risk except for melanoma (Iscovich et al, 1999). Both
investigations provided no data on HIV-infected persons and were
hampered by their relatively small size, which precluded detection
of increases in rare malignancies. 
Despite our study’s large size, we were limited in our ability to
identify a potential association for some rare malignancies (e.g.,
leukaemias). The study was also underpowered to detect associa-
tions for female-specific cancers because we had few women with
KS. However, there is no other evidence of a casual link between
these malignancies and KSHV. 
In summary, our study of individuals with AIDS demonstrated
an increased risk for IBL among persons with KS. This association
with KS was specific among malignancies, remained statistically
significant after adjustment for possible confounding factors, and
was consistent across subgroups defined by gender, HIV risk
group and race. Given the paucity of laboratory data on KSHV in
IBL, additional laboratory studies, particularly of IBLs arising
in persons with KS, are needed to determine whether KSHV plays
an aetiologic role. Further epidemiological studies will also be
informative. 
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